SF3B1 and plasma cell myeloma: It is noteworthy that all four patients in our study had only one common genomic aberration, that is, SF3B1. In addition, 2/4 patients (MDS2 and MDS3) had a lower mutation rate (2–4 mutations per exome), which is less as compared with that in AML (≈13), chronic lymphocytic leukaemia (≈12), and was significantly lower as compared with multiple myeloma (≈33), hence representing a much more homogenous clonal population.